Zogenix, Inc. (ZGNX) stock is lower by 2.24% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.
Zogenix, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ZGNX!
What is Stock Sentiment?
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With ZGNX Stock Today?
Zogenix, Inc. (ZGNX) stock is lower by -0.54% while the S&P 500 has risen 0.08% as of 1:04 PM on Thursday, Jul 22. ZGNX has fallen -$0.09 from the previous closing price of $17.57 on volume of 401,008 shares. Over the past year the S&P 500 is up 33.92% while ZGNX has fallen -37.35%. ZGNX lost -$4.30 per share in the over the last 12 months.
More About Zogenix, Inc.
Zogenix Inc is engaged in developing and commercializing therapeutic solutions for people living with serious and life-threatening rare CNS disorders and medical conditions. Its product candidate includes ZX008, low-dose fenfluramine for the treatment of Dravet syndrome, LGS, and potentially other rare and catastrophic epilepsy disorders.
Click Here to get the full Stock Report for Zogenix, Inc. stock.